Dermata Therapeutics (NASDAQ:DRMA) Upgraded to “Sell” at Wall Street Zen

Dermata Therapeutics (NASDAQ:DRMA) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Dermata Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

Dermata Therapeutics Stock Performance

Dermata Therapeutics stock opened at $2.25 on Friday. Dermata Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $23.70. The stock has a market cap of $2.32 million, a P/E ratio of -0.29 and a beta of 0.54. The firm’s fifty day moving average price is $2.46 and its 200-day moving average price is $4.16.

Dermata Therapeutics (NASDAQ:DRMA) last posted its earnings results on Friday, November 14th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.59) by ($0.06).

About Dermata Therapeutics

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.